Maternal Valacyclovir and Infant Cytomegalovirus Acquisition: A Randomized Controlled Trial among HIV-Infected WomenReportar como inadecuado




Maternal Valacyclovir and Infant Cytomegalovirus Acquisition: A Randomized Controlled Trial among HIV-Infected Women - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Background

Studies in HIV-1-infected infants and HIV-1-exposed, uninfected infants link early cytomegalovirus CMV acquisition with growth delay and cognitive impairment. We investigated maternal valacyclovir to delay infant acquisition of CMV.

Methods

Pregnant women with HIV-1, HSV-2 and CD4 count >250 cells-µl were randomized at 34 weeks gestation to 500 mg twice-daily valacyclovir or placebo for 12 months. Maternal CMV DNA was measured in plasma at 34 weeks gestation, in cervical secretions at 34 and 38 weeks gestation, and in breast milk at 7 postpartum timepoints; infant CMV DNA was measured in dried blood spots at 8 timepoints including birth.

Results

Among 148 women, 141 infants were compared in intent-to-treat analyses. Maternal and infant characteristics were similar between study arms. Infant CMV acquisition did not differ between study arms, with 46-70 infants 66% in placebo arm and 47-71 infants 66% in the valacyclovir arm acquiring CMV; median time to CMV detection did not differ. CMV DNA was detected in 92% of 542 breast milk specimens with no difference in CMV level between study arms. Change in cervical shedding of CMV DNA between baseline and 38 weeks was 0.40-log greater in the placebo arm than the valacyclovir arm p = 0.05.

Conclusions

In this cohort of HIV-1-seropositive mothers, two-thirds of infants acquired CMV by one year. Maternal valacyclovir had no effect on timing of infant CMV acquisition or breast milk CMV viral loads, although it modestly reduced cervical CMV shedding. Maternal prophylaxis to reduce infant CMV acquisition warrants further evaluation in trials with antiviral agents.

Trials Registration

ClinicalTrials.gov NCT00530777



Autor: Alison C. Roxby , Claire Atkinson, Kristjana Ásbjörnsdóttir, Carey Farquhar, James N. Kiarie, Alison L. Drake, Anna Wald, Mich

Fuente: http://plos.srce.hr/



DESCARGAR PDF




Documentos relacionados